Loading grant details…
Unlocking data content of Organ-On-Chips
| Funder | European Commission |
|---|---|
| Recipient Organization | Microfluidic Chipshop Gmbh |
| Country | Germany |
| Start Date | May 01, 2024 |
| End Date | Apr 30, 2027 |
| Duration | 1,094 days |
| Number of Grantees | 51 |
| Roles | Participant; Associated Partner; Third Party; Coordinator |
| Data Source | European Commission |
| Grant ID | 101140192 |
Grant Description
The launch of a novel drug to the market is preceded by clinical testing and validation both on animal in vitro and in vivo models. Animal models used in drug development have known methodological drawbacks leading to the failure of drugs. Further, animal tests are associated with ethical issues.
Moreover, a strong bias in in-human testing still overlooks major population groups e.g. children, women, different ethical groups.
It is estimated that 197,000 deaths per year in the EU are caused by Adverse Drug Reactions (ADRs) and the total cost to society of ADRs is €79 billion.
The emerging Organ-on-Chip (OOC) field, an alternative to animal test, brings great potential for safe testing and validation: An OOC-systems consists of a 3D-microstructured channel network embedded on a small plastic device that simulates the mechanics and physiological response of an entire organ or organs.
Project UNLOOC will develop, optimize, and validate a multitude of ECS-based tools to build OOC-models to replace animal and in-human testing.
UNLOOC aims to combine three important characteristics for routine use of OOC models, i.e platforms that combine ECS-based technologies with established biological material, capitalize on AI, parallelized test set-ups allowing efficient high-throughput demands, and standardized procedures enabling reliable results.
UNLOOC will develop ECS-based hardware and software tools and validate them in five Use Cases (UCs) performed in 10 European countries.
The applications developed and validated will be used by academia and pharma industry to drive drug development, create cosmetics without animal test, personalized medicine and gain new insights into disease.
Given the large OOC market, these solutions have great economic value, on average it would result in cost reduction of up to $169M and $706M per new drug reaching the market and will put Europe at the forefront of this booming research field (see impact section for details).
All Grantees
Abbvie Ireland Nl Bv; Cytes Biotechnologies Sl; Multi Channel Systems Mcs Gmbh; Micronit Bv; Stichting Imec Nederland; Csem Centre Suisse D'Electronique Et de Microtechnique Sa - Recherche Et Developpement; Locsense B.V.; Universidad de Zaragoza; Ihs Weigling Sociedad Limitada; Nederlandse Organisatie Voor Toegepast Natuurwetenschappelijk Onderzoek Tno; Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung Ev; Interuniversitair Micro-Electronica Centrum; Jobst Technologies Gmbh; Core Life Analytics Bv; Spiden Ag; Stelar Security Technology Law Research Ug (Haftungsbeschrankt) Gmbh; Fundacio Institut de Bioenginyeria de Catalunya; Universiteit Maastricht; Hun-Ren Energiatudomanyi Kutatokozpont; Universidad de Santiago de Compostela; Technische Universitaet Braunschweig; Okolab Srl; Nuromedia Gmbh; Lionix International Bv; Lipotype; Silicongate Lda; Universita Degli Studi Di Pavia; Fundacion Instituto de Investigacion Sanitaria Aragon; Viscofan Espana S.L.; Institutul National de Cercetaredezvoltare Pentru Microtehnologie; Ebers Medical Technology Sl; Fundacion de la Comunidad Valenciana Centro de Investigacion Principefelipe; Inesc Microsistemas E Nanotecnologias - Instituto de Engenharia de Sistemas E Computadores Para Os Microsistemas E As Nanotecnologias; Demcon Life Sciences & Health Enschede Bv; Philips Electronics Nederland Bv; I+Med S Coop; European Infrastructure of Open Screening Platforms for Chemical Biology European Research Infrastucture Consortium (Eu-Openscreen Eric); Carl Zeiss Microscopy Gmbh; Inesc Id - Instituto de Engenhariade Sistemas E Computadores, Investigacao E Desenvolvimento Em Lisboa; Beonchip Sl; Demcon Curonix Bv; Haute Ecole Specialisee de Suisse Occidentale; Demcon Sync Biosystems Bv; Ost - Ostschweizer Fachhochschule; Alveolix Ag; Insphero Ag; Universidad Del Pais Vasco/ Euskal Herriko Unibertsitatea; Microfluidic Chipshop Gmbh; University College Cork - National University of Ireland, Cork; Technische Universiteit Delft; Dds Diagnostic Srl
Interested in applying for this grant?
Complete our application form to express your interest and we'll guide you through the process.
Apply for This GrantQuick Summary
Related Grants
